Heidi Ledford for Nature writes (excerpt): “As companies increasingly focus on rare diseases and precision medicine tailored to a specific subset of patients, it has become more difficult to find willing volunteers who meet the necessary criteria. Recruitment...
New centers give study near complete coverage of North American FPC sites in drive to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer Immunovia AB today announced that four additional North American Familial Pancreatic...
Mike Novotny for EPM Magazine writes (excerpt) “Among the greatest factors behind the recruitment and retention struggles the industry faces are a wariness of unproven treatments (often referred to as the ‘guinea pig fear’) and the fact that, for many potential...
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a clinical trial update provided by GtreeBNT,...
Privo Technologies was granted the green light from the FDA and several hospitals this summer to begin patient recruitment for a prospective clinical trial (NCT03502148) targeting early-stage oral cavity squamous cell carcinoma (OCSCC). Privo is now actively...
Email
Text